Susquehanna Fundamental Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-70,900	Closed	-$1.16M	–	1171
2022 Q3	$1.16M	Buy	+70,900	New	+$1.15M	0.02%	759
2022 Q1	$1.27M	Sell	52,611 -4,949	-9%	-$120K	0.02%	741
2021 Q4	$1.34M	Buy	+57,560	New	+$1.16M	0.04%	542
2021 Q3	–	Sell	-59,698	Closed	-$1.46M	–	1678
2021 Q2	$1.46M	Buy	59,698 +22,722	+61%	+$513K	0.03%	704
2021 Q1	$954K	Buy	+36,976	New	+$1.63M	0.02%	905
2020 Q4	–	Sell	-78,600	Closed	-$3.24M	–	1473
2020 Q3	$3.24M	Hold	78,600	–	–	0.1%	279
2020 Q2	$3.81M	Buy	+78,600	New	+$3.77M	0.18%	137

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Susquehanna Fundamental Investments's ACAD Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 70,900 shares — an estimated $1.16M sold.

Susquehanna Fundamental Investments first reported a position in ACAD in Q2 2020 and held it in 7 quarters. The position peaked at $3.81M in Q2 2020. 228 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 70,900 Acadia Pharmaceuticals shares in Q4 2022, an estimated $1.16M.
Susquehanna Fundamental Investments first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's Acadia Pharmaceuticals position peaked at $3.81M in Q2 2020.
228 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.